May 28, 2020
Article
Fresenius Kabi is hoping to position itself in the US biosimilar market.
May 27, 2020
Article
The Association of Accessible Medicines (AAM), which supports biosimilar development, argues that even if the Affordable Care Act (ACA) is overturned by the Supreme Court later this year, the Biologics Price Competition and Innovation Act (BPCIA) is severable and should survive.
May 25, 2020
Article
Cost savings are likely to occur should payers switch from originator bevacizumab or rituximab to their respective biosimilars, according to research from 2 studies presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting.
May 23, 2020
Article
Samsung Bioepis announced positiive trial results for its ranibizumab biosimilar (SB11).
May 23, 2020
Article
Compared with use of originator products, use of biosimilars in the United States is apparently still not a priority of commercial health plans, according to the results of a recent JAMA study.
May 16, 2020
Article
Biosimilar developers can assuage some physician—and even patient—concerns through coordinated, evidence-based messaging.
May 15, 2020
Article
In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions, speakers said this week during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.
May 12, 2020
Article
How will coronavirus disease 2019 (COVID-19) affect prescription drug trends? The American Journal of Managed Care® (AJMC®) put questions to Chris Robbins, chief executive officer of Arxcel Consulting LLC, to review these subjects and more in a wrapup discussion after the Academy of Managed Care Pharmacy virtual meeting.
May 08, 2020
Article
A proposed bevacizumab biosimilar, BE1040V, was found to be noninferior to its reference product (Avastin) in terms of efficacy for the treatment of metastatic colorectal cancer (mCRC), according to a study published in Clinical Therapeutics.